BCABGeneral
CERTIFICATE OF MERGER MERGING BA MERGER SUB, INC. WITH AND INTO BIOATLA, INC. (Pursuant to Section 251 of the Delaware General Corporation Law) BioAtla, Inc., a corporation organized and existing under the Delaware Gener
BioAtla, Inc. has officially confirmed its merger with BA Merger Sub, Inc., as per Delaware General Corporation Law. The merger, which has been approved and acknowledged by both companies, is set to take effect on April 6, 2026. Following the merger, BioAtla will continue as the surviving corporation, retaining its name and structure. An executed copy of the merger agreement is available at BioAtla's office in San Diego, California.
Read more →BCABGeneral
▼ -16.4%on this news· ran to -42% by day 3shared move
BioAtla Announces Share Consolidation
BioAtla, Inc. has announced a 50-for-1 share consolidation effective April 6, 2026, to comply with Nasdaq's minimum bid price requirement. The consolidation was approved by stockholders during a special meeting. The company aims to enhance its stock price while continuing to develop its innovative CAB platform technology and pipeline of therapies for solid tumors.
Read more →BCABGeneral
▼ -16.4%on this news· ran to -42% by day 3shared move
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
BioAtla, Inc. reported its financial results for Q4 and full year 2025, highlighting a focus on advancing its Phase 1 study of BA3182 while exploring strategic options to enhance shareholder value. The company has seen a reduction in R&D and G&A expenses, but continues to face significant net losses. A reduction in workforce has been implemented to better align resources with corporate priorities.
Read more →BCABGeneral
▼ -17.5%on this news· ran to -32% by day 3
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
BioAtla, Inc. has announced a formal process to evaluate strategic options aimed at maximizing shareholder value, which may include asset sales or partnerships. The company is also implementing a significant restructuring plan, including a 70% workforce reduction. BioAtla has engaged Tungsten Advisors for guidance during this process, but outcomes remain uncertain.
Read more →BCABPhases
▼ -5.9%on this news· ran to -25% by day 3
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
BioAtla and GATC Health have announced a $40 million special purpose vehicle transaction to advance Ozuriftamab Vedotin (Oz-V) into a Phase 3 clinical trial for oropharyngeal squamous cell carcinoma (OPSCC). BioAtla will retain a 65% ownership stake in the asset, while GATC's Inversagen AI will hold 35%. The trial is expected to begin enrollment in early 2026, with potential for accelerated FDA approval.
Read more →BCABGeneral
▼ -25.1%on this news
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
BioAtla, Inc. has announced agreements for up to $22.5 million in flexible financing, including a $7.5 million advance and a Standby Equity Purchase Agreement for an additional $15 million. These agreements aim to provide financial flexibility as the company seeks to finalize a strategic partnership. The funding will support BioAtla's operations and ongoing clinical trials.
Read more →BCABGeneral
▲ +19.8%on this news· ran to +76% by day 3
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its third quarter 2025 financial results, highlighting FDA alignment on the Phase 3 Oz-V trial design and progress in its CAB T-cell engagers. The company experienced a decrease in R&D and G&A expenses, but reported a higher net loss compared to the previous year. BioAtla is on track to finalize a partnership transaction by year-end.
Read more →BCABPhases
▲ +7.2%on this news
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
BioAtla's Mecbotamab Vedotin (Mec-V) has demonstrated a median overall survival of 21.5 months in patients with treatment-refractory soft tissue sarcomas, significantly outperforming existing therapies. The safety profile of Mec-V, both as a monotherapy and in combination with anti-PD-1 antibody, remains manageable. This data was presented at the SITC 2025 Annual Meeting, highlighting the drug's potential in a challenging treatment landscape.
Read more →BCABConferences/Events
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
BioAtla, Inc. will host a conference call on November 13, 2025, to discuss its third-quarter financial results and business highlights. The call will take place at 4:30 p.m. ET, with details available on the company's website. BioAtla specializes in developing Conditionally Active Biologic antibody therapeutics for solid tumors.
Read more →BCABPhases
▲ +9.4%on this news
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
BioAtla presented a poster on ozuriftamab vedotin (Oz-V) at the IPVS Conference, detailing its mechanism targeting ROR2 in HPV+ oropharyngeal squamous cell carcinoma (OPSCC). The ADC demonstrated a 45% overall response rate in a Phase 2 trial. The FDA has granted Fast Track Designation, and preparations for a Phase 3 study are underway.
Read more →BCABPhases
▼ -26%on this newsshared move
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
BioAtla, Inc. presented promising interim data from its Phase 1 trial of BA3182 at ESMO 2025. The bispecific T-cell engager targets EpCAM and CD3, showing encouraging tumor control and a manageable safety profile. The therapy aims to minimize toxicity while effectively treating treatment-refractory metastatic adenocarcinoma, potentially benefiting over one million patients worldwide.
Read more →BCABConferences/Events
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla, Inc. announced that clinical data for its investigational ADC, mecbotamab vedotin (BA3011), will be presented at the SITC 2025 Annual Meeting. The presentation will highlight a median overall survival of 21.5 months among patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The event will take place from November 5-9, 2025, in National Harbor, MD.
Read more →BCABFDA Updates
▲ +13.9%on this news· ran to +44% by day 3
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla, Inc. announced positive outcomes from its Type B meeting with the FDA regarding Ozuriftamab vedotin for oropharyngeal squamous cell carcinoma (OPSCC). The FDA has outlined a pivotal trial design for full approval, with a focus on a significant improvement in overall response rates and overall survival. The company aims to initiate a Phase 3 study, highlighting the potential of its CAB platform technology.
Read more →BCABGeneral
▼ -7.2%on this news
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its financial results for Q2 2025, highlighting progress in its clinical programs, particularly the Phase 1 trial of BA3182. The company has reduced R&D expenses and is on track for a data readout later this year. However, it reported a net loss of $18.7 million and a significant decrease in cash reserves compared to the previous year.
Read more →BCABConferences/Events
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
BioAtla, Inc. will hold a conference call on August 7, 2025, to discuss its second quarter financial results and business highlights. The call will be accessible via webcast and includes dial-in options for participants. The company is focused on developing innovative antibody therapeutics for solid tumors and has multiple candidates in various clinical phases.
Read more →BCABConferences/Events
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
BioAtla, Inc. has announced an oral presentation at the 2025 ESMO TAT Asia Meeting in Hong Kong, scheduled for July 18-20, 2025. The presentation will showcase the company's advancements in Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. BioAtla's CAB platform is designed to enhance efficacy while reducing toxicity compared to traditional antibodies.
Read more →BCABPhases
▼ -5.4%on this news
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
BioAtla presented promising first-in-human data for BA3182, a bispecific T-cell engager targeting treatment refractory metastatic adenocarcinoma, at the ESMO Gastrointestinal Cancers Congress. The ongoing Phase 1 trial showed preliminary tumor reductions and a manageable safety profile. The company continues to escalate doses to determine the recommended Phase 2 dose.
Read more →BCABPhases
▲ +24.7%on this news
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BioAtla, Inc. presented promising Phase 2 clinical trial data for Ozuriftamab Vedotin (Oz-V) targeting HPV+ oropharyngeal squamous cell carcinoma (OPSCC) at the ASCO Annual Meeting. The trial reported a 45% overall response rate and a 100% disease control rate among patients who had received a median of 3 prior therapies. Oz-V demonstrated significant efficacy compared to current standard treatments, which only have a 3.4% response rate. The company plans to finalize the Phase 3 trial design with the FDA, aiming for potential accelerated approval.
Read more →BCABPhases
▼ -8.2%on this news
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla reported its financial results for the first quarter of 2025, highlighting significant progress in its clinical programs. The company is conducting a Phase 1 dose-escalation study for BA3182, which has dosed its first three patients, with data readout expected in mid-2025. Mecbotamab vedotin continues to show promising overall survival rates for mKRAS non-small cell lung cancer, while ozuriftamab vedotin demonstrates encouraging activity in HPV-positive head and neck cancer in its ongoing Phase 2 studies. With a current cash balance that supports operations through early 2026, BioAtla is positioned for key upcoming milestones.
Read more →BCABConferences/Events
BioAtla to Participate in the Citizens Life Sciences Conference
BioAtla, Inc. will participate in the Citizens Life Sciences Conference on May 7-8, 2025, in New York. The company's management will provide a corporate update and engage in one-on-one meetings with investors. BioAtla focuses on developing Condition Active Biologic antibody therapeutics for solid tumors and currently has multiple product candidates in various stages of clinical testing. Their innovative CAB platform technology aims to improve targeting and efficacy while reducing toxicity in cancer therapies.
Read more →BCABConferences/Events
▲ +11.4%on this news· ran to +25% by day 3shared move
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
BioAtla, a clinical-stage biotechnology company, announced it will host a conference call on May 6, 2025, to discuss its first quarter financial results. The company specializes in developing Conditionally Active Biologic antibody therapeutics for solid tumors, with multiple products at various clinical stages. This announcement reflects BioAtla's commitment to keeping stakeholders informed about its financial performance and ongoing projects, including the development of innovative cancer therapies.
Read more →BCABConferences/Events
▲ +19.9%on this news· ran to +30% by day 3shared move
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
BioAtla, Inc. announced the acceptance of two abstracts for poster presentations at the 2025 AACR Annual Meeting, showcasing its proprietary Conditionally Active Biologic (CAB) technology. The presentations will highlight differentiated preclinical activities of CAB products, including promising anti-Nectin4-antibody drug conjugates. The event is scheduled to take place from April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL. This scientific visibility may help bolster the company's position in the competitive oncology landscape.
Read more →BCABConferences/Events
▲ +10%on this news· ran to +32% by day 1shared move
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. has announced an upcoming poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will detail findings from a Phase 2 trial of ozuriftamab vedotin, targeting squamous cell carcinoma of the head and neck. This event will occur online and at McCormick Place Convention Center in Chicago from May 30 to June 3, 2025. The specific session is scheduled for June 2, 2025, from 9:00 AM to 12:00 PM CDT.
Read more →BCABPhases
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its financial results for Q4 and full year 2024, highlighting significant advancements in its clinical study programs. The Phase 1 trial for CAB-EpCAM x CAB-CD3 continues with promising results, while mecbotamab vedotin achieved notable overall survival rates in mKRAS NSCLC patients. Additionally, ozuriftamab vedotin showed substantial anti-tumor effects in HPV-positive squamous cell carcinoma. However, the company announced a workforce reduction to prioritize its internal programs and extend its financial resources into 2026.
Read more →BCABConferences/Events
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
BioAtla, Inc. has announced two accepted abstracts for poster presentations at the upcoming European Lung Cancer Congress 2025 in Paris and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 in Scottsdale. One presentation covers an exploratory analysis of overall survival among NSCLC patients with mutated KRAS, while the other discusses the Phase 2 experience of Ozuriftamab Vedotin in heavily pretreated head and neck cancer patients. These presentations highlight BioAtla's commitment to advancing treatments in oncology.
Read more →BCABConferences/Events
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
BioAtla, Inc. has announced its plans to host a conference call on March 27, 2025, to discuss financial results for the fourth quarter and full-year ended December 31, 2024, alongside business highlights. The company specializes in developing Conditionally Active Biologic antibody therapeutics aimed at treating solid tumors. BioAtla's product candidates focus on selective targeting and reduced toxicity, with promising candidates already in Phase 2 testing. A press release with detailed financial results will be available prior to the call, along with options for replaying the discussions on its website.
Read more →BCABGeneral
▼ -41.8%on this news
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
BioAtla, Inc. has announced a registered direct offering of 9,679,158 shares of common stock, aiming to raise approximately $9.2 million. The funds will be utilized to advance its mid-stage clinical programs, particularly the T-Cell Engager and Antibody Drug Conjugate programs. The offering price per share is $0.9520, and each share comes with a warrant. This move reflects the company's strategy to bolster its R&D funding and enhance its development pipeline.
Read more →BCABConferences/Events
▼ -41.8%on this news
Conditionally Active Biologics: Transforming Cancer Therapy Investor Presentation Non-Confidential December 2024 Important Notices & Disclaimers This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our",
BioAtla, Inc. recently presented an investor presentation highlighting its innovative 'Conditionally Active Biologics' (CAB) technology designed for targeted cancer therapy. The CAB technology aims to enhance therapeutic exposure and tumor selectivity while minimizing toxicity compared to traditional antibodies. The company operates multiple clinical and preclinical programs with promising preclinical data showcasing efficacy and safety in various cancer indications. While the company is well-positioned with ongoing clinical trials, it acknowledges uncertainties and competitive challenges in the rapidly evolving biopharma landscape.
Read more →BCABConferences/Events
▼ -6.9%on this news· ran to -18% by day 3
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla presented promising data on its drug Mecbotamab Vedotin (Mec-V) for treating advanced non-small cell lung cancer (NSCLC) with mutated KRAS at the IASLC 2024 conference. The study demonstrated a one-year overall survival rate of 58% in patients with mKRAS compared to 23% in those with wild-type KRAS. The drug showed efficacy across various mKRAS variants and was well tolerated with no new safety concerns reported. A randomized trial is planned for initiation in 2025 to further investigate Mec-V's potential in mKRAS NSCLC patients.
Read more →BCABConferences/Events
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla, Inc. has announced that it will present a poster on its research regarding the KRAS genotype and clinical outcomes in patients treated with Mecbotamab Vedotin at the IASLC 2024 meeting in Washington, DC. The presentation is scheduled for December 14, 2024, during a designated poster reception session. BioAtla's work focuses on Conditionally Active Biologic therapeutics for solid tumors, with ongoing Phase 2 clinical testing for key candidates.
Read more →BCABPhases
▲ +7.8%on this news
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its third quarter 2024 financial results, highlighting significant progress in its clinical trials. Notably, Ozuriftamab vedotin has shown durable responses in head and neck cancer, while Evalstotug has demonstrated tumor reductions in melanoma patients. Mecbotamab vedotin also exhibited improved overall survival rates in NSCLC patients with specific KRAS mutations. Additionally, the company secured a licensing agreement expected to support operations through early 2026.
Read more →BCABConferences/Events
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
BioAtla, Inc. has announced its plans to host a conference call on November 7, 2024, to discuss its third quarter financial results for the period ending September 30, 2024, along with business highlights. The company, which focuses on developing Conditionally Active Biologic antibody therapeutics for solid tumors, is advancing several CAB programs, including two in Phase 2 clinical testing. This announcement indicates ongoing progress in their pipeline and business operations.
Read more →BCABConferences/Events
▼ -6.4%on this news
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. has announced a poster presentation for its ongoing research on evalstotug (BA3071) at the 39th Society for Immunotherapy of Cancer Annual Meeting in November 2024. The study will present updated results from a phase 1 trial exploring the drug's effectiveness in advanced solid tumors when used with or without nivolumab. This presentation will take place at the George R. Brown Convention Center in Houston, TX, showcasing BioAtla's commitment to advancing its Conditionally Active Biologic antibody therapeutics.
Read more →BCABConferences/Events
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
BioAtla, Inc. has announced that an abstract for its new CAB anti-CTLA-4 antibody, evalstotug, has been accepted for oral presentation at the Society for Melanoma Research 21st International Congress in October 2024. This presentation will detail the antibody's designed capabilities for enabling high exposures and reduced immune-mediated toxicity. The event represents a significant opportunity for BioAtla to showcase its innovative approach in the treatment of solid tumors, potentially advancing its clinical programs.
Read more →BCABGeneral
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BioAtla, Inc. has entered an agreement with Context Therapeutics to license BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Under this agreement, Context will receive the exclusive rights to develop and commercialize BA3362, while BioAtla will earn potential milestone payments totaling up to $133.5 million, including an upfront payment of $15 million. This move allows BioAtla to concentrate on its lead clinical programs, with Context aiming for an IND filing for BA3362 by mid-2026. This agreement underscores the strategic value of both companies' collaborative efforts in oncology.
Read more →BCABPhases
▼ -7.2%on this news
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
BioAtla presented encouraging Phase 2 clinical trial data for ozuriftamab vedotin at the 2024 ESMO Annual Meeting. The trial involved 32 heavily pretreated patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The data revealed a 32% overall response rate and a disease control rate of 77%, with the treatment demonstrating manageable tolerability. The company plans to meet with the FDA regarding a potential registrational trial later in 2024.
Read more →BCABConferences/Events
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
BioAtla, Inc. has announced a poster presentation at the 2024 European Society for Medical Oncology Annual Meeting in Barcelona. The presentation will focus on the Phase 2 trial of ozuriftamab vedotin, a conditionally active biologic targeting recurrent or metastatic squamous cell carcinoma of the head and neck. The event is scheduled for September 14, and the presentation materials will be available on BioAtla's website post-event. This announcement reflects BioAtla's commitment to developing its cutting-edge antibody therapeutics.
Read more →BCABConferences/Events
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
BioAtla, Inc. (Nasdaq: BCAB), a biotechnology company specializing in Conditionally Active Biologic therapeutics, will showcase a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. The pre-recorded presentation will be available on-demand beginning September 9 at 7:00 a.m. ET. BioAtla focuses on developing novel therapies for solid tumors and has several innovative antibody drug conjugates currently in clinical trials. The company has robust patent coverage and partnerships enhancing its developmental capabilities.
Read more →BCABFDA Updates
▲ +5.8%on this news
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its financial results for the second quarter of 2024, highlighting significant advancements in its clinical pipeline. The FDA granted Fast Track Designation to ozuriftamab vedotin for use in squamous cell carcinoma of the head and neck. Both evalstotug and mecbotamab vedotin are showing promising results in ongoing trials, particularly with improved efficacy in patients with specific tumor mutations. The company's financial position remains stable, with sufficient funding to support operations through the next year and a half as they advance toward potential registrational trials.
Read more →BCABConferences/Events
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
BioAtla, Inc. announced it will host a conference call and webcast on August 8, 2024, to discuss its financial results for the second quarter ending June 30, 2024, and to provide key business highlights. The call will include details on its progress in developing Conditionally Active Biologic therapeutics for solid tumors. The company has multiple programs in various stages of clinical testing, indicating a robust pipeline. Interested participants can access the webcast and dial-in information from the company's website.
Read more →BCABPhases
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
BioAtla, Inc. presented updates on its clinical programs during a virtual R&D Day, highlighting the Phase 2 study results for mecbotamab vedotin (CAB-AXL-ADC) in non-small cell lung cancer (NSCLC) patients with mutant KRAS variants. The company reported promising clinical responses and a strong safety profile for its novel anti-CTLA-4 antibody, evalstotug, in combination with PD-1. Key opinion leaders shared their enthusiasm for the therapies' effectiveness and manageable side effects. BioAtla emphasizes its commitment to developing conditionally active biologics for various solid tumors.
Read more →BCABFDA Updates
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc. has received Fast Track Designation from the FDA for ozuriftamab vedotin, a targeted therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. This designation highlights the therapy's potential to meet unmet medical needs in a patient population with limited treatment options. Promising clinical results were reported from Phase 2 trials, showing activity in treatment-refractory patients. The company plans to seek FDA guidance for a potential registrational trial in the second half of 2024.
Read more →BCABConferences/Events
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
BioAtla, Inc. (Nasdaq: BCAB) announced it will host a virtual R&D Day on July 25, 2024, to present updates on its clinical programs and pipeline. The company specializes in Conditionally Active Biologic (CAB) therapeutics, with two of its CAB programs currently in Phase 2 testing. Additionally, the press release details extensive patent coverage for BioAtla's technology and product candidates. However, it also highlights various risks and uncertainties associated with clinical trials and regulatory processes.
Read more →BCABConferences/Events
▼ -9.5%on this news
BioAtla to Participate in the Jefferies Global Healthcare Conference
BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biotechnology firm, will participate in the Jefferies Global Healthcare Conference scheduled for June 4-6, 2024. The company's management will engage in a fireside chat and conduct one-on-one meetings with investors on June 5. BioAtla is recognized for its development of Conditionally Active Biologic (CAB) therapeutics targeting solid tumors and has multiple programs in clinical testing, including anti-cancer antibody-drug conjugates.
Read more →BCABPhases
▼ -7.9%on this news· ran to -33% by day 3shared move
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. is set to present promising Phase 1 clinical trial data at the 2024 ASCO Annual Meeting regarding its anti-CTLA-4 agent, evalstotug. The data showcases extended progression-free survival of over 10 months in refractory patients, along with manageable safety profiles. The company is on track to launch a Phase 3 trial in the second half of 2024, highlighting the agent's potential as a best-in-class treatment option in combination with PD-1 therapy. The presentation will take place on June 1, 2024, at the McCormick Place Convention Center in Chicago.
Read more →BCABPhases
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla reported strong first quarter 2024 financial results, highlighting clinical progress in several programs, including positive Phase 2 data for ozuriftamab vedotin in SCCHN and promising results for evalstotug in melanoma. The company anticipates multiple FDA meetings for potential registrational trials later this year. Financially, BioAtla's cash reserves of $80.6 million are expected to sustain operations until the second half of 2025, while net losses continue to decline year-over-year.
Read more →BCABConferences/Events
BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biotechnology company, announced its participation in the upcoming Citizens JMP Life Sciences Conference in New York on May 13-14, 2024. The company's management will engage in a fireside chat and individual investor meetings, reflecting its commitment to developing innovative antibody therapeutics targeting solid tumors. BioAtla's novel CAB technology aims to improve efficacy and reduce toxicity compared to traditional treatment methods. This participation highlights the company's active presence in the biotech space as it advances its clinical programs.
Read more →BCABConferences/Events
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
BioAtla, Inc. (Nasdaq: BCAB) will hold a conference call and webcast on May 14, 2024, to discuss its first quarter 2024 financial results and business highlights. The company focuses on developing Conditionally Active Biologic antibody therapeutics for solid tumors and has a strong pipeline, with two first-in-class CAB drugs currently in Phase 2 clinical testing. BioAtla's innovative CAB technology provides advantages over traditional antibody therapies, including selectivity and reduced toxicity.
Read more →BCABFDA Updates
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
BioAtla, Inc. announced that the FDA has cleared its investigational new drug application for BA3361, a CAB-Nectin-4 antibody drug conjugate targeted for multiple tumors. This ADC utilizes a NextGen linker system designed to minimize off-target toxicities while enhancing potency. Preclinical data suggest that BA3361 could achieve significant efficacy and reduced toxicity compared to current treatment options such as enfortumab vedotin. The development of BA3361 aligns with BioAtla's commitment to innovative therapeutic solutions in oncology.
Read more →BCABConferences/Events
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. has announced a poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, focusing on the Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic. This study investigates its use in combination with nivolumab for advanced solid tumors. The session is scheduled for June 1, 2024, in Chicago, highlighting the company's advancements in antibody therapeutics aimed at enhancing efficacy while reducing toxicity. Presentation materials will be available on BioAtla's website following the session.
Read more →BCABPhases
▲ +29.2%on this news· ran to +48% by day 1
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its fourth quarter and full year 2023 financial results, highlighting significant progress across its clinical programs, particularly its CAB-CTLA-4 (BA3071) study which cleared the dose-limiting toxicity observation period. The company anticipates key data readouts in the second quarter of 2024 for its BA3071 monotherapy and combination studies. Additionally, BioAtla confirmed its cash reserves are sufficient to fund operations through the second half of 2025 despite a net loss of $26.9 million for Q4 2023.
Read more →BCABConferences/Events
▲ +5.1%on this news
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
BioAtla, Inc. will host a conference call on March 26, 2024, to discuss its financial results for Q4 and the full year ending December 31, 2023. The call will provide business highlights and is part of the company's active engagement with investors. BioAtla specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. The company boasts significant patent coverage and has multiple candidates in advanced clinical stages.
Read more →BCABConferences/Events
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
BioAtla, Inc. has announced that five of its research abstracts will be presented at the 2024 AACR Annual Meeting in San Diego. The presentations will highlight BioAtla's proprietary Conditionally Active Biologic technology, including an antibody drug conjugate that surpasses existing models in efficacy. Notably, findings on T-cell engagers indicated no toxicities in preclinical non-human primate studies. The meeting is set to take place from April 5-10, 2024, with specific sessions dedicated to the tumor microenvironment and antibody research.
Read more →BCABGeneral
Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation January 2024 Important Notices & Disclaimers This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or th
BioAtla, Inc. presented its corporate strategy highlighting its focus on Conditionally Active Biologics (CABs) aimed at transforming cancer therapy. The company is advancing multiple clinical trials, including two Phase 2 CAB-ADCs and a Phase 1 dual CAB. BioAtla reported a strong cash position as of September 30, 2023, which is expected to support significant milestones in their pipeline into 2024. The presentation underscores the potential benefits of CAB technology in improving patient outcomes across various solid tumors.
Read more →BCABConferences/Events
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
BioAtla, Inc. will participate in the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 8-11, 2024, in San Francisco. The company plans to engage in a fireside chat and hold one-on-one meetings with investors during the event. BioAtla focuses on developing Conditionally Active Biologic (CAB) antibody therapeutics for treating solid tumors and is currently advancing several CAB product candidates in clinical testing. This participation marks a significant opportunity for BioAtla to enhance its presence in the biopharmaceutical sector.
Read more →BCABConferences/Events
▲ +23.3%on this news
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
BioAtla, Inc. hosted a virtual R&D Day to present data on their Phase 1 trial for BA3071, a conditionally active antibody targeting CTLA-4. The trial demonstrated confirmed clinical responses and durable disease control in patients with multiple solid tumors. The company noted a favorable safety profile and intends to explore higher doses in ongoing Phase 2 studies, both as monotherapy and in combination with a PD-1 inhibitor. Overall, the preliminary results indicate promising therapeutic potential for BA3071 in treating cancers previously resistant to existing therapies.
Read more →BCABConferences/Events
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
BioAtla, Inc. has announced a virtual R&D Day scheduled for December 13, 2023, to present Phase 1 trial results of BA3071, a novel antibody targeting CTLA-4 in solid tumors. The presentation will be led by Dr. Omid Hamid, a prominent figure in immuno-oncology research. BA3071 is in Phase 2 development for solid tumors and aims to demonstrate efficacy similar to existing treatments, but with reduced toxicity. The event will include a live Q&A session following the presentation.
Read more →BCABPhases
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
BioAtla, Inc. recently presented promising Phase 2 clinical trial data for BA3011, a CAB-AXL antibody-drug conjugate targeting non-small cell lung cancer (NSCLC), at the IASLC 2023 Conference. The trial showed notable clinical benefits in heavily pre-treated patients, including a 27.8% objective response rate. The results indicate a potential for this treatment to advance into a registrational study, especially given its significant activity among AXL-positive patients. Overall, the data supports BioAtla's ongoing commitment to develop CAB-AXL-ADC for NSCLC.
Read more →BCABPhases
▼ -22.6%on this newsshared move
Phase 2 Trial of Mecbotamab Vedotin (BA3011), CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non- Squamous NSCLC BA3011
BioAtla is conducting a Phase 2 trial of Mecbotamab Vedotin (BA3011), administered alone or in combination with Nivolumab, for patients with non-squamous non-small cell lung cancer (NSCLC). The trial demonstrated promising efficacy signals, with a recorded median duration of response of 4.8 months in monotherapy. The combination therapy also showed an ongoing complete response in one patient. However, the study reported a significant occurrence of treatment-emergent adverse events, particularly in the combination therapy group, which requires careful evaluation moving forward.
Read more →BCABConferences/Events
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
BioAtla, Inc. announced its participation in the JMP Securities Hematology and Oncology Summit, scheduled for December 5-6, 2023. The company will engage in a fireside chat and one-on-one investor meetings to discuss its advancements. BioAtla focuses on Conditionally Active Biologics (CAB) for treating solid tumors and has multiple candidates in clinical testing. With over 700 patents, the company emphasizes its innovative approaches in developing antibody therapeutics.
Read more →BCABConferences/Events
▲ +8.2%on this news· ran to +20% by day 3shared move
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
BioAtla, Inc. announced it will host a virtual KOL event on December 4, 2023, reviewing Phase 2 clinical trial data for its drug BA3011 in treating refractory non-small cell lung cancer (NSCLC). The event will feature Dr. Carl M. Gay from MD Anderson Cancer Center, who will discuss therapeutic resistance factors related to AXL in NSCLC. BA3011, an antibody-drug conjugate targeting AXL, has shown promise for patients who have not responded to existing therapies. This event comes shortly before the presentation of related data at the IASLC 2023 conference in Chicago.
Read more →BCABPhases
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
BioAtla reported strong financial results for Q3 2023 alongside updates on its clinical programs, highlighting notable clinical responses in ongoing studies for CAB-AXL-ADC, CAB-ROR2-ADC, and CAB-CTLA-4. Positive FDA feedback indicates support for advancing CAB-AXL-ADC towards potential registrational studies. Furthermore, the company maintains a robust cash position projected to sustain operations into the second half of 2025, despite an increase in net losses and R&D expenses compared to the previous year.
Read more →BCABConferences/Events
BioAtla to Participate in the Jefferies London Healthcare Conference
BioAtla, Inc. (Nasdaq: BCAB), a biotechnology firm focused on Conditionally Active Biologic therapeutics, is set to participate in the Jefferies London Healthcare Conference from November 14-16, 2023. The company's management will engage in a fireside chat and one-on-one meetings with investors on November 15. BioAtla is developing innovative antibody therapeutics, including two first-in-class CAB programs currently undergoing Phase 2 clinical trials. The firm is recognized for its strong patent portfolio and novel technologies aimed at improved cancer treatments.
Read more →BCABGeneral
▼ -5.5%on this news
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
BioAtla, Inc. announced that its CEO and cofounder, Dr. Jay M. Short, has been awarded the Lowell Thomas Award by The Explorers Club for his significant contributions to scientific innovation. The award recognizes excellence in exploration and is symbolic of the advancements presented in various fields. Dr. Short's leadership in developing the CAB platform for antibody therapeutics underscores BioAtla's potential in cancer treatment. This recognition adds to Dr. Short's notable achievements in the biotechnology sector.
Read more →BCABConferences/Events
▲ +15.1%on this newsshared move
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
BioAtla, Inc. (Nasdaq: BCAB) announced its plans to host a conference call on November 7, 2023, to discuss third quarter 2023 financial results and business updates. The company has submitted an abstract on its CAB-AXL-ADC program for non-small cell lung cancer at an upcoming conference, and an R&D day is scheduled for December 13, 2023, to focus on the Phase 1/2 trial of BA3071. BioAtla continues to leverage its proprietary technology for further advancements in oncology treatments.
Read more →BCABConferences/Events
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
BioAtla, Inc. (Nasdaq: BCAB) is set to participate in the H.C. Wainwright 25th Annual Global Investment Conference, occurring from September 11-13, 2023. The company will provide a corporate update and engage in one-on-one investor meetings, highlighting its focus on Conditionally Active Biologics (CAB) for solid tumors. BioAtla has multiple candidates in clinical testing, including two first-in-class CAB programs currently in Phase 2 trials, showcasing its innovative approach in the biotechnology sector.
Read more →BCABConferences/Events
BioAtla to Participate in Upcoming Investor Conferences in August
BioAtla, Inc. (Nasdaq: BCAB), a biotechnology company focused on Conditionally Active Biologic antibody therapeutics, announced its upcoming participation in two investor conferences in August 2023. The BTIG Virtual Biotechnology Conference is scheduled for August 7, followed by the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17. BioAtla is known for its innovative CAB technology, aimed at improving the effectiveness and safety of treatments for solid tumors.
Read more →BCABPhases
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its financial results for Q2 2023, highlighting significant advancements in its clinical programs, particularly for its CAB-AXL-ADC, BA3011, targeting various solid tumors. The company has managed to clear its fifth patient cohort without dose-limiting toxicities, and it remains on track for FDA feedback regarding its NSCLC trial in the second half of 2023. Despite a net loss increase and higher R&D expenses compared to the previous year, BioAtla's cash reserves are expected to support ongoing operations through 2025. Upcoming data readouts and ongoing trials across multiple indications are set to provide key milestones in the coming months.
Read more →BCABConferences/Events
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
BioAtla, Inc. will host a conference call on August 1, 2023, to discuss its second quarter 2023 financial results and business highlights. As a clinical-stage biotechnology company, BioAtla focuses on Conditionally Active Biologic (CAB) therapeutics for solid tumors. The company boasts extensive patent coverage and is advancing multiple drug candidates, including two in Phase 2 clinical testing. The event is accessible to both domestic and international audiences via dial-in and webcast.
Read more →BCABGeneral
▼ -9.4%on this news
BioAtla Added to Membership of U.S. Small-Cap Russell 2000 Index
BioAtla, Inc. has been added to the U.S. small-cap Russell 2000 Index as of June 26, 2023, which will enhance its visibility and credibility in the market. The company is known for developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors. BioAtla has a significant patent portfolio and is currently progressing multiple clinical-stage products. This addition to the index coincides with the annual reconstitution of the Russell indexes.
Read more →BCABConferences/Events
BioAtla to Participate in the Jefferies Healthcare Conference
BioAtla, Inc. announced its participation in the upcoming Jefferies Healthcare Conference to be held in New York from June 7-9, 2023. The company will engage in a fireside chat and conduct one-on-one meetings with investors, emphasizing its role as a clinical-stage biotechnology firm focused on Conditionally Active Biologic (CAB) therapies. BioAtla offers a range of advanced antibody therapeutics aimed at treating solid tumors, which are currently in various stages of clinical testing. With a robust patent portfolio, the company aims to enhance efficacy while reducing toxicity in cancer treatments.
Read more →BCABPhases
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its first quarter 2023 financial results, highlighting ongoing progress in key clinical trials for its CAB therapeutics, including BA3011 and BA3021. The company expects to submit a meeting request to the FDA regarding BA3011 for non-small cell lung cancer in 1H23 and continue enrolling patients in various Phase 2 studies. With a cash balance of $192.7 million, BioAtla anticipates funding its operations through 2025 despite reporting a higher net loss compared to the previous year. Management remains focused on advancing therapies for solid tumors with high unmet medical needs.
Read more →BCABConferences/Events
▼ -9.4%on this newsshared move
BioAtla to Participate in the JMP Securities Life Sciences Conference
BioAtla, Inc. announced its participation in the JMP Securities Life Sciences Conference set for May 15-16, 2023, in New York City. The company will provide a corporate update and hold one-on-one investor meetings during the event. BioAtla is focused on developing Conditionally Active Biologics (CAB) aimed at treating solid tumors, with two products currently in Phase 2 testing. The company boasts an extensive patent portfolio supporting its innovative therapeutic approach.
Read more →BCABConferences/Events
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
BioAtla, Inc. has announced a conference call scheduled for May 11, 2023, at 4:30 p.m. ET to discuss its financial results for Q1 2023 and provide business highlights. The company specializes in the development of Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors. BioAtla currently has two CAB programs in Phase 2 clinical testing and extensive patent coverage for its technologies. More details will be available through its website prior to the call.
Read more →BCABPhases
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
BioAtla, Inc. reported its financial results and clinical progress for 2022, highlighting advancements in several Phase 2 trials targeting various solid tumors. The company has achieved first patient in milestones for its CAB-ADC product candidates and received FDA clearance for a new investigational drug. With a cash balance of $215.5 million, BioAtla is well-positioned to fund its ongoing programs through 2025. The management is optimistic about upcoming readouts and maintaining momentum in their clinical research efforts.
Read more →BCABConferences/Events
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
BioAtla, Inc. plans to host a conference call on March 23, 2023, to discuss its financial results for the fourth quarter and full-year 2022. The company, focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, will also provide business highlights during the call. BioAtla has two CAB programs currently in Phase 2 clinical testing, emphasizing its commitment to innovation in the biotechnology sector.
Read more →BCABGeneral
BioAtla Announces Change in Executive Leadership
BioAtla, Inc. announced the departure of its President, Scott Smith, who is moving to become the CEO of Viatris. Smith has played a crucial role in BioAtla's growth and success since joining in 2018 and will remain involved with the company as a Board member. His leadership experience has been vital in driving the company's clinical programs and operational strategies. BioAtla's Chairman expressed gratitude for Smith's impact while highlighting the continued importance of his contributions in his new role.
Read more →BCABFDA Updates
▼ -8.8%on this newsshared move
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
BioAtla, Inc. announced that the FDA has cleared its investigational new drug application for BA3182, a CAB-EpCAMxCAB-CD3 bispecific T-cell engager targeting advanced adenocarcinoma. The company intends to initiate a Phase 1 clinical study in 2023, aiming to explore the drug's safety and efficacy. BA3182 distinguishes itself by binding more selectively in the tumor microenvironment, which may enhance its therapeutic index compared to traditional therapies. This development signifies an important step in BioAtla’s expanding oncology pipeline.
Read more →BCABPhases
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
BioAtla, Inc. announced significant updates regarding its clinical programs and upcoming milestones during the 41st Annual J.P. Morgan Healthcare Conference. Notable progress includes the positive interim results of its Phase 2 trial of mecbotamab vedotin (BA3011) in PD-1 refractory non-small cell lung cancer (NSCLC) patients, demonstrating strong antitumor activity. The company is also initiating Phase 2 part 2 studies for undifferentiated pleomorphic sarcoma and continues advancing its BA3071 clinical program. BioAtla remains optimistic about the prospects for 2023 with multiple significant inflection points expected in its clinical pipeline.
Read more →BCABConferences/Events
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s m
Read more →BCABGeneral
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed t
Read more →BCABGeneral
BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled
BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated to begin by year-end
CAB-CTLA-4 (BA3071)
Read more →BCABPhases
BA3011 Supplemental NSCLC and Sarcoma Data 10/2022 1 AXL BA3011-002 (Phase 2 Part 1) - Disposition as of October 2022 24 patients enrolled 6 patients on-going with 0 scan (3 combo) Preliminary Data 2 patients not dosed y
AXL BA3011-002 (Phase 2 Part 1) - Disposition as of October 2022 24
patients enrolled 6 patients on-going with 0 scan (3 combo) Preliminary Data 2 patients not dosed yet 2 withdrawal of consent early, before the first scan 14 efficacy-evaluable patients* ORR: 5/14 (36%) 12 Non-S
Read more →BCABGeneral
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to hos
Read more →BCABGeneral
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in 4Q22
Mecbotamab vedotin (BA3011) Undifferentiated Pleomorphic Sarcoma (UPS) and
Read more →BCABConferences/Events
▲ +5.8%on this news
BioAtla to Participate in the 2022 BTIG Biotechnology Conference
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s m
Read more →BCABGeneral
▲ +5.2%on this news· ran to +20% by day 3shared move
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to hos
Read more →BCABConferences/Events
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, P
Read more →BCABGeneral
▲ +6.5%on this news· ran to -44% by day 3
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –
– Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first half 2022; interim update projected on 2Q22 earnings call –
– Ozuriftamab vedot
Read more →BCABConferences/Events
TRANSFORMING CANCER THERAPY April 2022 Needham & Co Annual Healthcare Conference 1 ` Important Notices & Disclaimers This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company"
Annual Healthcare Conference 1 `
Important Notices & Disclaimers This presentation (the
"Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of
Read more →BCABGeneral
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference
Read more →BCABGeneral
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo (nivolumab) for Treatment of Solid Tumors SAN DIEGO, CA
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo (nivolumab) for Treatment of Solid Tumors
SAN DIEGO, CA January 10, 2022 - BioAtla, Inc. (Nasdaq: BCAB), a global c
Read more →BCABPhases
BIOATLA ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES Proceeds to advance CAB-AXL and CAB-ROR2 through potentially registration enabling Phase 2 clinical trials, and additional CAB development programs SAN DIEGO, CA
BIOATLA ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES
Proceeds to advance CAB-AXL and CAB-ROR2 through potentially registration enabling Phase 2 clinical trials, and additional CAB development programs
SAN DIEGO, CA September 29, 2021 - BioAtla, Inc. (Nasdaq: BCAB), a globa
Read more →BCABGeneral
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
SAN DIEGO and BEIJING, China and CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160
Read more →